|
1
|
Spolverato G, Ejaz A, Azad N and Pawlik
TM: Surgery for colorectal liver metastases: The evolution of
determining prognosis. World J Gastrointest Oncol. 5:207–221. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lemmens VE, Klaver YL, Verwaal VJ, Rutten
HJ, Coebergh JW and de Hingh IH: Predictors and survival of
synchronous peritoneal carcinomatosis of colorectal origin: A
population-based study. Int J Cancer. 128:2717–2725. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Saltz LB, Clarke S, Díaz-Rubio E,
Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS,
Rivera F, et al: Bevacizumab in combination with oxaliplatin-based
chemotherapy as first-line therapy in metastatic colorectal cancer:
A randomized phase III study. J Clin Oncol. 26:2013–2019. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sobrero AF, Maurel J, Fehrenbacher L,
Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C,
Steinhauer EU, Prausova J, et al: EPIC: Phase III trial of
cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin
failure in patients with metastatic colorectal cancer. J Clin
Oncol. 26:2311–2319. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Goldberg RM, Sargent DJ, Morton RF, Fuchs
CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC and Alberts
S: Randomized controlled trial of reduced-dose bolus fluorouracil
plus leucovorin and irinotecan or infused fluorouracil plus
leucovorin and oxaliplatin in patients with previously untreated
metastatic colorectal cancer: A North American Intergroup Trial. J
Clin Oncol. 24:3347–3353. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hurwitz H, Fehrenbacher L, Novotny W,
Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S,
Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and
leucovorin for metastatic colorectal cancer. N Engl J Med.
350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
ClinicalTrials.gov ClinicalTrials.gov
Identifier: NCT00003594: Combination Chemotherapy in Treating
Patients With Advanced Colorectal Cancer. http://clinicaltrials.gov/show/NCT00003594March
10–2017
|
|
8
|
ClinicalTrials.gov ClinicalTrials.gov
Identifier: NCT00005036: Irinotecan Compared With Combination
Chemotherapy in Treating Patients With Advanced Colorectal Cancer.
http://clinicaltrials.gov/show/NCT00005036March
10–2017
|
|
9
|
Franko J, Shi Q, Goldman CD, Pockaj BA,
Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR and Sargent
DJ: Treatment of colorectal peritoneal carcinomatosis with systemic
chemotherapy: A pooled analysis of north central cancer treatment
group phase III trials N9741 and N9841. J Clin Oncol. 30:263–267.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Maehara Y, Hasuda S, Koga T, Tokunaga E,
Kakeji Y and Sugimachi K: Postoperative outcome and sites of
recurrence in patients following curative resection of gastric
cancer. Br J Surg. 87:353–357. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sadeghi B, Arvieux C, Glehen O, Beaujard
AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL,
Faure JL, et al: Peritoneal carcinomatosis from non-gynecologic
malignancies: Results of the EVOCAPE 1 multicentric prospective
study. Cancer. 88:358–363. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yamaguchi H, Kitayama J, Ishigami H, Emoto
S, Yamashita H and Watanabe T: A phase 2 trial of intravenous and
intraperitoneal paclitaxel combined with S-1 for treatment of
gastric cancer with macroscopic peritoneal metastasis. Cancer.
119:3354–3358. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Heidelberger C, Birnie GD, Boohar J and
Wentland D: Fluorinated pyrimidines. XX. Inhibition of the
nucleoside phosphorylase cleavage of 5-fluoro-2′-deoxyuridine by
5-trifluoromethyl-2′-deoxyuridine. Biochim Biophys Acta.
76:315–318. 1963. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gottschling H and Heidelberger C:
Fluorinated pyrimidines: XIX some biological effects of
5-trifluoromthyluracil and 5-trifluoromethyl-2′-deoxyuridine of
Escherichia coli and bacteriophage T4 G. J Mol Biol. 7:541–560.
1963. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Reyes P and Heidelberger C: Fluorinated
pyrimidines. XXVI. Mammalian thymidylate synthetase: Its mechanism
of action and inhibition by fluorinated nucleotides. Mol Pharmacol.
1:14–30. 1965.PubMed/NCBI
|
|
16
|
Fujiwara Y, Oki T and Heidelberger C:
Fluorinated pyrimidines. XXXVII. Effects of
5-trifluoromethyl-2′-deoxyuridine on the synthesis of
deoxyribonucleic acid of mammalian cells in culture. Mol Pharmacol.
6:273–280. 1970.PubMed/NCBI
|
|
17
|
Fukushima M, Suzuki N, Emura T, Yano S,
Kazuno H, Tada Y, Yamada Y and Asao T: Structure and activity of
specific inhibitors of thymidine phosphorylase to potentiate the
function of antitumor 2′-deoxyribonucleosides. Biochem Pharmacol.
59:1227–1236. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Emura T, Suzuki N, Yamaguchi M, Ohshimo H
and Fukushima M: A novel combination antimetabolite, TAS-102,
exhibits antitumor activity in FU-resistant human cancer cells
through a mechanism involving FTD incorporation in DNA. Int J
Oncol. 25:571–578. 2004.PubMed/NCBI
|
|
19
|
Lenz HJ, Stintzing S and Loupakis F:
TAS-102, a novel antitumor agent: A review of the mechanism of
action. Cancer Treat Rev. 41:777–783. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mayer RJ, van Cutsem E, Falcone A, Yoshino
T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero
J, Komatsu Y, et al: Randomized trial of TAS-102 for refractory
metastatic colorectal cancer. N Engl J Med. 372:1909–1919. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bando H, Doi T, Muro K, Yasui H, Nishina
T, Yamaguchi K, Takahashi S, Nomura S, Kuno H, Shitara K, et al: A
multicenter phase II study of TAS-102 monotherapy in patients with
pre-treated advanced gastric cancer (EPOC1201). Eur J Cancer.
62:46–53. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
ClinicalTrials.gov ClinicalTrials.gov
Identifier: NCT02500043: Study of TAS-102 or Placebo Plus BSC in
Patients With Metastatic Gastric Cancer. http://clinicaltrials.gov/show/NCT02500043March
10–2017
|
|
23
|
Murakami Y, Kazuno H, Emura T, Tsujimoto
H, Suzuki N and Fukushima M: Different mechanisms of acquired
resistance to fluorinated pyrimidines in human colorectal cancer
cells. Int J Oncol. 17:277–283. 2000.PubMed/NCBI
|
|
24
|
Motoyama T, Hojo H and Watanabe H:
Comparison of seven cell lines derived from human gastric
carcinomas. Acta Pathol Jpn. 36:65–83. 1986.PubMed/NCBI
|
|
25
|
Kasuya K, Nagakawa Y, Suzuki M, Suzuki Y,
Kyo B, Suzuki S, Matsudo T, Itoi T, Tsuchida A and Aoki T:
Combination therapy of gemcitabine or oral S-1 with the anti-VEGF
monoclonal antibody bevacizumab for pancreatic neuroendocrine
carcinoma. Exp Ther Med. 3:599–602. 2012.PubMed/NCBI
|
|
26
|
Guo XF, Yang ZR, Wang J, Lei XF, Lv XG and
Dong WG: Synergistic antitumor effect of puerarin combined with
5-fluorouracil on gastric carcinoma. Mol Med Rep. 11:2562–2568.
2015.PubMed/NCBI
|
|
27
|
Kawato Y, Furuta T, Aonuma M, Yasuoka M,
Yokokura T and Matsumoto K: Antitumor activity of a camptothecin
derivative, CPT-11, against human tumor xenografts in nude mice.
Cancer Chemother Pharmacol. 28:192–198. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Arjumand W and Sultana S: Glycyrrhizic
acid: A phytochemical with a protective role against
cisplatin-induced genotoxicity and nephrotoxicity. Life Sci.
89:422–429. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tanaka N, Sakamoto K, Okabe H, Fujioka A,
Yamamura K, Nakagawa F, Nagase H, Yokogawa T, Oguchi K, Ishida K,
et al: Repeated oral dosing of TAS-102 confers high trifluridine
incorporation into DNA and sustained antitumor activity in mouse
models. Oncol Rep. 32:2319–2326. 2014.PubMed/NCBI
|
|
30
|
Suzuki N, Emura T and Fukushima M: Mode of
action of trifluorothymidine (TFT) against DNA replication and
repair enzymes. Int J Oncol. 39:263–270. 2011.PubMed/NCBI
|
|
31
|
Grogan BC, Parker JB, Guminski AF and
Stivers JT: Effect of the thymidylate synthase inhibitors on dUTP
and TTP pool levels and the activities of DNA repair glycosylases
on uracil and 5-fluorouracil in DNA. Biochemistry. 50:618–627.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Markley JC, Chirakul P, Sologub D and
Sigurdsson ST: Incorporation of 2′-deoxy-5-(trifluoromethyl)uridine
and 5-cyano-2′-deoxyuridine into DNA. Bioorg Med Chem Lett.
11:2453–2455. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kerbel RS: Human tumor xenografts as
predictive preclinical models for anticancer drug activity in
humans: Better than commonly perceived-but they can be improved.
Cancer Biol Ther. 2 4 Suppl 1:S134–S139. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang C, Awasthi N, Schwarz MA and Schwarz
RE: Establishing a peritoneal dissemination xenograft mouse model
for survival outcome assessment of experimental gastric cancer. J
Surg Res. 182:227–234. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gould SE, Junttila MR and de Sauvage FJ:
Translational value of mouse models in oncology drug development.
Nat Med. 21:431–439. 2015. View
Article : Google Scholar : PubMed/NCBI
|
